Prognostic value of lymphocyte-to-monocyte ratio and systemic immune-inflammation index in non-small-cell lung cancer patients with brain metastases

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 68(1), 7–30 (2018). • Lung cancer is the most common malignant cancer and the leading cause of cancer-related deaths worldwide.
  MedlineGoogle Scholar
• 2. Bray F, Ferlay J, Soerjomataram I et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
  MedlineGoogle Scholar
• 3. Ettinger DS, Bepler G, Bueno R et al. Non-small cell lung cancer clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 4(6), 548–582 (2006).
  Medline CASGoogle Scholar
• 4. Taillibert S, Le Rhun E. Epidemiology of brain metastases. Cancer Radiother. 19(1), 3–9 (2015).
  Medline CASGoogle Scholar
• 5. Sperduto PW, Norbert K, David R et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J. Clin. Oncol. 30(4), 419–425 (2015).
  Google Scholar
• 6. Gaspar LE, Scott C, Murray K, Curran W. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 47(4), 1001–1006 (2000).
  Medline CASGoogle Scholar
• 7. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int. J. Radiat. Oncol. Biol. Phys. 70(2), 510–514 (2008).
  MedlineGoogle Scholar
• 8. Sperduto PW, Yang TJ, Beal K et al. Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol. 3(6), 827–831 (2016).
  Google Scholar
• 9. Lorenzoni J, Devriendt D, Massager N et al. Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems. Int. J. Radiat. Oncol. Biol. Phys. 60(1), 218–224 (2004).
  MedlineGoogle Scholar
• 10. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 357(9255), 539–545 (2001). •• Illustrates the complicated relationship between inflammation and cancer.
  Medline CASGoogle Scholar
• 11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646–674 (2011).
  Medline CASGoogle Scholar
• 12. Suzuki K, Kachala SS, Kadota K et al. Prognostic immune markers in non-small cell lung cancer. Clin. Cancer Res. 17(16), 5247–5256 (2011).
  Medline CASGoogle Scholar
• 13. Bocchialini G, Lagrasta C, Madeddu D et al. Spatial architecture of tumour-infiltrating lymphocytes as a prognostic parameter in resected non-small-cell lung cancer. Eur. J. Cardiothorac. Surg. doi:10.1093/ejcts/ezaa098 (2020).
  MedlineGoogle Scholar
• 14. Armani G, Madeddu D, Mazzaschi G et al. Blood and lymphatic vessels contribute to the impact of the immune microenvironment on clinical outcome in non-small-cell lung cancer. Eur. J. Cardiothorac. Surg. 53(6), 1205–1213 (2018).
  MedlineGoogle Scholar
• 15. Mori M, Shuto K, Kosugi C et al. An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer. BMC Cancer 18(1), 1261–1265 (2018).
  MedlineGoogle Scholar
• 16. Huang HP, Liu Q, Zhu LX et al. Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer. Sci. Rep. 9(1), 3284 (2019).
  MedlineGoogle Scholar
• 17. Zhang K, Hua YQ, Wang D et al. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer. J. Transl. Med. 17(1), 30 (2019).
  MedlineGoogle Scholar
• 18. Patel DA, Xi J, Luo JQ et al. Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer. Breast Cancer Res. Treat. 174(2), 443–452 (2019).
  MedlineGoogle Scholar
• 19. Chen MF, Chen PT, Kuan FC et al. The predictive value of pretreatment neutrophil-to-lymphocyte ratio in esophageal squamous cell carcinoma. Ann. Surg. Oncol. 26(1), 190–199 (2019).
  MedlineGoogle Scholar
• 20. Yamamoto A, Toiyama Y, Okugawa Y et al. Clinical implications of pretreatment: lymphocyte-to-monocyte ratio in patients with rectal cancer receiving preoperative chemoradiotherapy. Dis. Colon Rectum 62(2), 171–180 (2019).
  MedlineGoogle Scholar
• 21. Gao XP, Liu YH, Liu ZY et al. Pretreatment lymphocyte-to-monocyte ratio as a predictor of survival among patients with ovarian cancer: a meta-analysis. Cancer Manag. Res. 11, 1907–1920 (2019).
  Medline CASGoogle Scholar
• 22. Kousuke W, Atsushi Y, Yosuke A et al. Mean platelet volume and lymphocyte-to-monocyte ratio are associated with shorter progression-free survival in EGFR-mutant lung adenocarcinoma treated by EGFR tyrosine kinase inhibitor. PLoS ONE 13(9), e0203625 (2018). • The lymphocyte-to-monocyte ratiois an important prognostic factor in non-small-cell lung cancer.
  MedlineGoogle Scholar
• 23. Coussens LM, Werb Z. Inflammation and cancer. Nature 420(6917), 860–867 (2002).
  Medline CASGoogle Scholar
• 24. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 454(7203), 436–444 (2008).
  Medline CASGoogle Scholar
• 25. Bausch D, Pausch T, Krauss T et al. Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma. Angiogenesis 14(3), 235–243 (2011).
  Medline CASGoogle Scholar
• 26. Kuang DM, Zhao QY, Wu Y et al. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J. Hepatol. 54(5), 948–955 (2011).
  Medline CASGoogle Scholar
• 27. Brandau S, Dumitru CA, Lang S. Protumor and antitumor functions of neutrophil granulocytes. Semin. Immunopathol. 35(2), 163–176 (2013).
  Medline CASGoogle Scholar
• 28. Schumacher D, Strilic B, Sivaraj KK et al. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell 24(1), 130–137 (2013).
  Medline CASGoogle Scholar
• 29. Stanger BZ, Kahn ML. Platelets and tumor cells: a new form of border control. Cancer Cell 24(1), 9–11 (2013).
  Medline CASGoogle Scholar
• 30. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20(5), 576–590 (2011).
  Medline CASGoogle Scholar
• 31. Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett. 267(2), 204–215 (2008).
  Medline CASGoogle Scholar
• 32. Ferrone C, Dranoff G. Dual roles for immunity in gastrointestinal cancers. J. Clin. Oncol. 28(26), 4045–4051 (2010).
  Medline CASGoogle Scholar
• 33. Stotz M, Pichler M, Absenger G et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br. J. Cancer 110(2), 435–440 (2014).
  Medline CASGoogle Scholar
• 34. Sun Y, Zhang L. The clinical use of pretreatment NLR, PLR, and LMR in patients with esophageal squamous cell carcinoma: evidence from a meta-analysis. Cancer Manag. Res. 10, 6167–6179 (2018).
  MedlineGoogle Scholar
• 35. Guo W, Lu X, Liu Q et al. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: an updated meta-analysis of 17079 individuals. Cancer Med. 8(9), 4135–4148 (2019).
  Medline CASGoogle Scholar
• 36. Wang X, Su S, Guo Y. The clinical use of the platelet to lymphocyte ratio and lymphocyte to monocyte ratio as prognostic factors in renal cell carcinoma: a systematic review and meta-analysis. Oncotarget 8(48), 84506–84514 (2017).
  MedlineGoogle Scholar
• 37. Zhang Y, Xiao G, Wang R. Clinical significance of systemic immune-inflammation index (SII) and C-reactive protein-to-albumin ratio (CAR) in patients with esophageal cancer: a meta-analysis. Cancer Manag. Res. 11, 4185–4200 (2019).
  Medline CASGoogle Scholar
• 38. Wang Z, Zhan P, Lv Y et al. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis. Transl. Lung Cancer Res. 8(3), 214–226 (2019).
  Medline CASGoogle Scholar
• 39. Mori M, Shuto K, Kosugi C et al. An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer. BMC Cancer 18(1), 1261–1265 (2018).
  MedlineGoogle Scholar
• 40. Yang L, Huang Y, Zhou L et al. High pretreatment neutrophil-to-lymphocyte ratio as a predictor of poor survival prognosis in head and neck squamous cell carcinoma: systematic review and meta-analysis. Head Neck 41(5), 1525–1535 (2019).
  MedlineGoogle Scholar
• 41. Li Z, Xu Z, Huang Y et al. Prognostic values of preoperative platelet-to-lymphocyte ratio, albumin and hemoglobin in patients with non-metastatic colon cancer. Cancer Manag. Res. 11, 3265–3274 (2019).
  Medline CASGoogle Scholar
• 42. Liu J, Shi Z, Bai Y et al. Prognostic significance of systemic immune-inflammation index in triple-negative breast cancer. Cancer Manag. Res. 11, 4471–4480 (2019).
  Medline CASGoogle Scholar
• 43. Tong YS, Tan J, Zhou XL et al. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. J. Transl. Med. 15(1), 221 (2017). • Systemic immune-inflammation index is an independent prognostic indicator of poor outcomes for patients with non-small-cell lung cancer.
  MedlineGoogle Scholar
• 44. Song Q, Wu JZ, Wang S. Low preoperative lymphocyte to monocyte ratio serves as a worse prognostic marker in patients with esophageal squamous cell carcinoma undergoing curative tumor resection. J. Cancer 10(9), 2057–2062 (2019).
  MedlineGoogle Scholar
• 45. Kawai M, Hirono S, Okada K et al. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer. Surgery 165(6), 1151–1160 (2019).
  MedlineGoogle Scholar
• 46. Goto W, Kashiwagi S, Asano Y et al. Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer. BMC Cancer 18(1), 1137 (2018).
  Medline CASGoogle Scholar
• 47. Wei H, Su M, Lin R, Li H, Zou C. Prognostic factors analysis in EGFR mutation-positive non-small cell lung cancer with brain metastases treated with whole brain-radiotherapy and EGFR-tyrosine kinase inhibitors. Oncol. Lett. 11(3), 2249–2254 (2016).
  Medline CASGoogle Scholar
• 48. Li WY, Zhao TT, Xu HM et al. The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis. BMC Cancer 19(1), 145 (2019).
  MedlineGoogle Scholar
• 49. Johung KL, Yao X, Li F et al. A clinical model for identifying radiosensitive tumor genotypes in non-small cell lung cancer. Clin. Cancer Res. 19(19), 5523–5532 (2013).
  Medline CASGoogle Scholar
• 50. Porta R, Sánchez-Torres JM, Paz-Ares L et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur. Respir. J. 37(3), 624–631 (2011).
  Medline CASGoogle Scholar
• 51. Iuchi T, Shingyoji M, Sakaida T et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer 82(2), 282–287 (2013).
  Medline CASGoogle Scholar
• 52. Wu YL, Zhou C, Cheng Y et al. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). Ann. Oncol. 24(4), 993–999 (2013).
  MedlineGoogle Scholar
• 53. Dong K, Liang W, Zhao S et al. EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases. Transl. Lung Cancer Res. 8(3), 268–279 (2019).
  Medline CASGoogle Scholar
• 54. Diem S, Schmid S, Krapf M et al. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer 111, 176–181 (2017).
  MedlineGoogle Scholar
• 55. Ferrucci PF, Ascierto PA, Pigozzo J et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann. Oncol. 27(4), 732–738 (2016).
  Medline CASGoogle Scholar